Tuesday, September 29, 2020 6:18:58 PM
Dow Jones 9/29/20 9:31 AM ET
CHARLOTTESVILLE, VA / ACCESSWIRE / September 29, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that the U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the Assure/FaStep(R) COVID-19 IgG/IgM Rapid Test Device. This marks the first FDA EUA for a serology (antibody) point-of-care (POC) test for COVID-19 using fingerstick blood samples as compared with current approved tests that only utilize serum, plasma, or a venous blood draw. See the FDA news release here.
As a result of the FDA's EUA, fingerstick blood samples can now be utilized with the FaStep COVID-19 IgG/IgM Rapid Test Device for the test in POC settings, including doctors' offices, hospitals, urgent care centers, emergency rooms, or other locations where there is a licensed healthcare professional. The FaStep COVID-19 IgG/IgM Rapid Test Device was initially authorized for emergency use in July 2020 to help identify individuals with antibodies to SARS-CoV-2, indicating recent or prior COVID-19 infection, but as with all competing rapid COVID-19 test kits, was not yet authorized for fingerstick blood sample use.
Adial has commenced sales of the FaStep COVID-19 IgG/IgM rapid antibody test kits to healthcare providers and hospitals through The iRemedy Healthcare Companies, Inc. (iRemedy) network and ecommerce platform. See here. Antibody test kits distributed by Adial are lateral flow assay, 10-minute, 'instant' point-of-care test devices for the qualitative detection of lgG and lgM antibodies specific to SARS-CoV-2 virus in fingerstick whole blood, venous whole blood, serum, and plasma. During testing, the specimen reacts with antigen coated particles in the test cassette after droplets of blood from the subject are placed on the cassette's coated membrane.
William Stilley, Chief Executive Officer of Adial Pharmaceuticals, commented, "The issuance of the EUA for the first point-of-care antibody test for COVID-19 in the U.S. using fingerstick blood samples is expected to provide an important competitive advantage, which should support more widespread adoption of the Assure/FaStep COVID-19 IgG/IgM Rapid Test Device as a fast, convenient and reliable method for COVID-19 serology testing. We see a market demand for these instant and efficient antibody tests to help combat the international COVID-19 pandemic with the addressable global COVID-19 rapid test kits market expected to reach $3.52 billion by the end of 2020."
https://ir.adialpharma.com/press-releases/detail/94/adial-pharmaceuticals-announces-covid-19-point-of-care
Recent ADIL News
- Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office • GlobeNewswire Inc. • 04/22/2024 12:30:00 PM
- Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder • GlobeNewswire Inc. • 04/10/2024 12:30:00 PM
- Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update • GlobeNewswire Inc. • 04/02/2024 12:30:00 PM
- Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds • GlobeNewswire Inc. • 03/02/2024 12:00:00 AM
- Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office • GlobeNewswire Inc. • 02/28/2024 02:30:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:22:13 PM
- Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office • GlobeNewswire Inc. • 02/13/2024 02:15:24 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/25/2024 09:30:56 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/25/2024 05:15:07 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 09:15:23 PM
- Adial Announces Appointment of Tony Goodman as Chief Operating Officer • GlobeNewswire Inc. • 01/18/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 09:17:10 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/12/2024 09:51:29 PM
- Adial Pharmaceuticals Receives Final Reimbursement Payment from Adovate • GlobeNewswire Inc. • 12/20/2023 02:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 12/12/2023 09:36:31 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/08/2023 04:08:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/29/2023 09:47:52 PM
- Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement • GlobeNewswire Inc. • 11/29/2023 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/28/2023 09:10:09 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/24/2023 02:24:17 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/20/2023 12:46:55 PM
- Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/14/2023 10:02:55 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 11/08/2023 09:05:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2023 11:14:31 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM